論文・学術発表 | 株式会社ステムリム

2022年

Synthesized HMGB1 peptide prevents the progression of inflammation, steatosis, fibrosis, and tumor occurrence in a non-alcoholic steatohepatitis mouse model

Yui Ishii (1), Atsunori Tsuchiya (1), Kazuki Natsui (1), Youhei Koseki (1), Nobutaka Takeda (1), Kei Tomiyoshi (1), Fusako Yamazaki (1), Yuki Yoshida (1), Takashi Shimbo (2)(3), Katsuto Tamai (2), Shuji Terai (1)
Affiliations
(1) Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
(2) Department of Stem Cell Therapy Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
(3) StemRIM Institute of Regeneration-Inducing Medicine, Osaka University, Suita, Osaka, Japan.
Hepatol Res. 2022 Dec;52(12):985-997. doi: 10.1111/hepr.13825. Epub 2022 Aug 18.
PMID: 35932481 DOI: 10.1111/hepr.13825

Single-cell transcriptome analysis of fractional CO 2 laser efficiency in treating a mouse model of alopecia

Kouichi Hasegawa (1)(2), Takahiro Fujimoto (3), Chihiro Mita (1)(2), Hidehiro Furumoto (1)(2), Masako Inoue (1)(2), Kentaro Ikegami (1)(2), Tomomi Kitayama (1)(2)(4), Yukari Yamamoto (1)(2), Takashi Shimbo (2)(4), Takehiko Yamazaki (1)(2), Katsuto Tamai (2)(4)
Affiliations
(1) Drug Discovery Department, StemRIM Incorporation, Osaka, Japan.
(2) StemRIM Institute of Regeneration-Inducing Medicine, Osaka University, Osaka, Japan.
(3) Clinic F, Tokyo, Japan.
(4) Department of Stem Cell Therapy Science, Graduate School of Medicine, Osaka University, Osaka, Japan.
Lasers Surg Med. 2022 Oct;54(8):1167-1176. doi: 10.1002/lsm.23590. Epub 2022 Aug 2.
PMID: 35916125 DOI: 10.1002/lsm.23590

2021年

Synthesized HMGB1 peptide attenuates liver inflammation and suppresses fibrosis in mice.

Shunsuke Nojiri (1), Atsunori Tsuchiya (2), Kazuki Natsui (1), Suguru Takeuchi (1), Takayuki Watanabe (1), Yuichi Kojima (1), Yusuke Watanabe (1), Hiroteru Kamimura (1), Masahiro Ogawa (1), Satoko Motegi (1), Takahiro Iwasawa (1), Takeki Sato (1), Masaru Kumagai (1), Yui Ishii (1), Tomomi Kitayama (3)(4), Yu-Tung Li (3), Yuya Ouchi (3)(4), Takashi Shimbo (3)(5), Masaaki Takamura (1), Katsuto Tamai (3), Shuji Terai (6)
Affiliations
(1) Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University.
(2) Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University.
(3) Department of Stem Cell Therapy Science, Graduate School of Medicine, Osaka University.
(4) StemRIM Inc.
(5) StemRIM Institute of Regeneration-Inducing Medicine.
(6) Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University.
Inflamm Regen. 2021 Sep 27;41(1):28.
PMID: 34565478 PMCID: PMC8474861 DOI: 10.1186/s41232-021-00177-4

2020年

High-mobility group box 1 fragment suppresses adverse post-infarction remodeling by recruiting PDGFRalpha-positive bone marrow cells.

Takasumi Goto (1), Shigeru Miyagawa (1), Katsuto Tamai (2), Ryohei Matsuura (1), Takashi Kido (1), Toru Kuratani (3), Kazuo Shimamura (3), Ryoto Sakaniwa (4), Akima Harada (1), Yoshiki Sawa (1)
Affiliations
(1) Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
(2) Department of Stem Cell Therapy Science, Osaka University Graduate School of Medicine, Osaka, Japan.
(3) Department of Minimally Invasive Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
(4) Department of Social Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
PLoS One. 2020 Apr 10;15(4):e0230392. doi: 10.1371/journal.pone.0230392. eCollection 2020.
PMID: 32275672 PMCID: PMC7147742

2018年

The administration of high-mobility group box 1 fragment prevents deterioration of cardiac performance by enhancement of bone marrow mesenchymal stem cell homing in the delta-sarcoglycan-deficient hamster.

Takashi Kido (1), Shigeru Miyagawa (1), Takasumi Goto (1), Katsuto Tamai (2), Takayoshi Ueno (1), Koichi Toda (1), Toru Kuratani (1), Yoshiki Sawa (1)
Affiliations
(1) Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
(2) Department of Stem Cell Therapy Science, Osaka University Graduate School of Medicine, Osaka, Japan.
PLoS One. 2018 Dec 5;13(12):e0202838. doi: 10.1371/journal.pone.0202838. eCollection 2018.
PMID: 30517097 PMCID: PMC6281303

2016年

Stem Cell Therapy for Epidermolysis Bullosa-Does It Work?

Katsuto Tamai (1), Jouni Uitto (2)
Affiliations
(1) Department of Stem Cell Therapy Science, Osaka University Graduate School of Medicine, Osaka, Japan.
(2) Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA; Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
J Invest Dermatol. 20162016 Nov;136(11):2119-2121.
doi: 10.1016/j.jid.2016.07.004. PMID: 27772543

2015年

Endogenous mesenchymal stromal cells in bone marrow are required to preserve muscle function in mdx mice.

Ryo Fujita (1), Katsuto Tamai, Eriko Aikawa, Keisuke Nimura, Saki Ishino, Yasushi Kikuchi, Yasufumi Kaneda
Affiliation
(1) Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, Osaka, Japan.
Stem Cells. 2015 Mar;33(3):962-75.
doi: 10.1002/stem.1900. PMID: 25408548

Transplanted bone marrow-derived circulating PDGFRα+ cells restore type VII collagen in recessive dystrophic epidermolysis bullosa mouse skin graft.

Shin Iinuma (1), Eriko Aikawa (2), Katsuto Tamai (3), Ryo Fujita (4), Yasushi Kikuchi (2), Takenao Chino (2), Junichi Kikuta (5), John A McGrath (6), Jouni Uitto (7), Masaru Ishii (5), Hajime Iizuka (8), Yasufumi Kaneda (4)
Affiliations
(1) Department of Stem Cell Therapy Science, Graduate School of Medicine, Osaka University ; Division of Gene Therapy Science, Graduate School of Medicine, Osaka University ; Department of Dermatology, Asahikawa Medical College;
(2) Department of Stem Cell Therapy Science, Graduate School of Medicine, Osaka University;
(3) Department of Stem Cell Therapy Science, Graduate School of Medicine, Osaka University;
(4) Division of Gene Therapy Science, Graduate School of Medicine, Osaka University;
(5) Immunology and Cell Biology, Graduate School of Medicine, Osaka University;
(6) Department of Molecular Dermatology, King's College,; and.
(7) Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College at Thomas Jefferson University.
(8) Department of Dermatology, Asahikawa Medical College;
J Immunol. 2015 Feb 15;194(4):1996-2003. doi: 10.4049/jimmunol.1400914. Epub 2015 Jan 19.
PMID: 25601922 PMCID: PMC4319308

Systemic high-mobility group box 1 administration suppresses skin inflammation by inducing an accumulation of PDGFRα(+) mesenchymal cells from bone marrow.

Eriko Aikawa (1), Ryo Fujita (2), Yasushi Kikuchi (1), Yasufumi Kaneda (2), Katsuto Tamai (1)
Affiliations
(1) Department of Stem Cell Therapy Science, Graduate School of Medicine, Osaka University, Japan.
(2) Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, Japan.
Sci Rep. 2015 Jun 5;5:11008.
doi: 10.1038/srep11008. PMID: 26046579 PMCID: PMC4457135

2011年

PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia.

Katsuto Tamai (1), Takehiko Yamazaki, Takenao Chino, Masaru Ishii, Satoru Otsuru, Yasushi Kikuchi, Shin Iinuma, Kotaro Saga, Keisuke Nimura, Takashi Shimbo, Noriko Umegaki, Ichiro Katayama, Jun-ichi Miyazaki, Junji Takeda, John A McGrath, Jouni Uitto, Yasufumi Kaneda
Affiliation
(1) Division of Gene Therapy Science, Osaka University Graduate School of Medicine
Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6609-14. doi: 10.1073/pnas.1016753108.
PMID: 21464317 PMCID: PMC3081004